Abstract
SP021 Bone marrow minimal residual disease (MRD) was the strongest predictor of survival from high risk metastatic neuroblastoma (NB) following anti-GD2 immunotherapy, when tested in multivariate models that include FcR polymorphism and missing ligand for inhibitory killer-immunoglobulin-like receptor (KIR)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
